{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:13Z","timestamp":1794096013764,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Wu Jieping Medical Foundation","award":["320.6750.2024-6-111"],"award-info":[{"award-number":["320.6750.2024-6-111"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05292-y","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:39:22Z","timestamp":1775648362000},"page":"14039-14053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world safety signals of baricitinib and in silico exploration of a potential mechanism underlying herpes zoster: a multidisciplinary analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Yulei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-2708","authenticated-orcid":false,"given":"Quan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"3","key":"5292_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4(3):130\u2013136","journal-title":"Autoimmun Rev"},{"issue":"13","key":"5292_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372","journal-title":"JAMA"},{"key":"5292_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.antiviral.2019.01.009","volume":"163","author":"AM Altman","year":"2019","unstructured":"Altman AM, Mahmud J, Nikolovska-Coleska Z, Chan G (2019) Hcmv modulation of cellular PI3K\/AKT\/mTOR signaling: new opportunities for therapeutic intervention? Antivir Res 163:82\u201390","journal-title":"Antivir Res"},{"issue":"5","key":"5292_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jtha.2023.01.027","volume":"21","author":"JD Beckman","year":"2023","unstructured":"Beckman JD, DaSilva A, Aronovich E, Nguyen A, Nguyen J, Hargis G et al (2023) JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions. J Thromb Haemost 21(5):1366\u20131380","journal-title":"J Thromb Haemost"},{"key":"5292_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285455","volume":"14","author":"Y Bian","year":"2023","unstructured":"Bian Y, Xiang Z, Wang Y, Ren Q, Chen G, Xiang B et al (2023) Immunomodulatory roles of metalloproteinases in rheumatoid arthritis. Front Pharmacol 14:1285455","journal-title":"Front Pharmacol"},{"issue":"4 Suppl 55","key":"5292_CR6","first-page":"S112","volume":"27","author":"A Boonen","year":"2009","unstructured":"Boonen A, Mau W (2009) The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4 Suppl 55):S112\u2013S117","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5292_CR7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s10067-019-04815-8","volume":"39","author":"E Bouajina","year":"2020","unstructured":"Bouajina E, Zakraoui L, Kchir M, Kochbati S, Baklouti S (2020) Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice. Clin Rheumatol 39(5):1449\u20131455","journal-title":"Clin Rheumatol"},{"issue":"11","key":"5292_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008037","volume":"15","author":"J Buehler","year":"2019","unstructured":"Buehler J, Carpenter E, Zeltzer S, Igarashi S, Rak M, Mikell I et al (2019) Host signaling and EGR1 transcriptional control of human cytomegalovirus replication and latency. PLoS Pathog 15(11):e1008037","journal-title":"PLoS Pathog"},{"key":"5292_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1089001","volume":"14","author":"J Chen","year":"2023","unstructured":"Chen J, Qin S, Liu S, Zhong K, Jing Y, Wu X et al (2023) Targeting matrix metalloproteases in diabetic wound healing. Front Immunol 14:1089001","journal-title":"Front Immunol"},{"issue":"7","key":"5292_CR10","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/1756-185X.13013","volume":"21","author":"IA Choi","year":"2018","unstructured":"Choi IA, Park SH, Cha HS, Park W, Kim HA, Yoo DH et al (2018) Prevalence of co-morbidities and evaluation of their monitoring in Korean patients with rheumatoid arthritis: comparison with the results of an international, cross-sectional study (COMORA). Int J Rheum Dis 21(7):1414\u20131422","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"5292_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253\u201362","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"5292_CR12","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.1128\/JVI.00214-16","volume":"90","author":"O Cojohari","year":"2016","unstructured":"Cojohari O, Peppenelli MA, Chan GC (2016) Human cytomegalovirus induces an atypical activation of Akt to stimulate the survival of short-lived monocytes. J Virol 90(14):6443\u20136452","journal-title":"J Virol"},{"issue":"9","key":"5292_CR13","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10067-023-06654-0","volume":"42","author":"B Conley","year":"2023","unstructured":"Conley B, Bunzli S, Bullen J, O\u2019Brien P, Persaud J, Gunatillake T et al (2023) What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. Clin Rheumatol 42(9):2267\u201378","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5292_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88\u201395","journal-title":"Ann Rheum Dis"},{"issue":"11 Pt A","key":"5292_CR15","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.bbamcr.2017.05.010","volume":"1864","author":"B Fingleton","year":"2017","unstructured":"Fingleton B (2017) Matrix metalloproteinases as regulators of inflammatory processes. Biochim Biophys Acta Mol Cell Res 1864(11 Pt A):2036\u20132042","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"13","key":"5292_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u201352","journal-title":"N Engl J Med"},{"issue":"4 Suppl 73","key":"5292_CR17","first-page":"S107","volume":"30","author":"M Her","year":"2012","unstructured":"Her M, Kavanaugh A (2012) Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis. Clin Exp Rheumatol 30(4 Suppl 73):S107-11","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"5292_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74(2):333\u2013340","journal-title":"Ann Rheum Dis"},{"key":"5292_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810546","author":"HS Lee","year":"2022","unstructured":"Lee HS, Kim WJ (2022) The role of matrix metalloproteinase in inflammation with a focus on infectious diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231810546","journal-title":"Int J Mol Sci"},{"key":"5292_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104714","volume":"177","author":"W Li","year":"2020","unstructured":"Li W, Xu C, Hao C, Zhang Y, Wang Z, Wang S et al (2020) Inhibition of herpes simplex virus by myricetin through targeting viral gD protein and cellular EGFR\/PI3K\/Akt pathway. Antiviral Res 177:104714","journal-title":"Antiviral Res"},{"issue":"7S Suppl 2","key":"5292_CR21","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1097\/RHU.0000000000001361","volume":"26","author":"E Mysler","year":"2020","unstructured":"Mysler E, Cardiel MH, Xavier RM, L\u00f3pez A, Ramos-Esquivel A (2020) Subcutaneous tocilizumab in monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs in Latin American patients with moderate to severe active rheumatoid arthritis: a multicenter, phase IIIb study. J Clin Rheumatol 26(7S Suppl 2):S180-s6","journal-title":"J Clin Rheumatol"},{"issue":"18","key":"5292_CR22","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1056\/NEJMc2202778","volume":"386","author":"A Ozdede","year":"2022","unstructured":"Ozdede A, Yaz\u0131c\u0131 H (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(18):1766","journal-title":"N Engl J Med"},{"issue":"2","key":"5292_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102343","volume":"48","author":"F Sanie-Jahromi","year":"2025","unstructured":"Sanie-Jahromi F, Arman A, Attar A, Nowroozzadeh MH (2025) A systematic review of the potential treatment effects of topical epidermal growth factor for ocular surface disorders. Cont Lens Anterior Eye 48(2):102343","journal-title":"Cont Lens Anterior Eye"},{"issue":"12","key":"5292_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16(12):843\u201362","journal-title":"Nat Rev Drug Discov"},{"issue":"10188","key":"5292_CR25","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303\u201311","journal-title":"Lancet"},{"issue":"8","key":"5292_CR26","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012697","volume":"12","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ et al (2020) Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 12(8):e12697","journal-title":"EMBO Mol Med"},{"issue":"3","key":"5292_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133\u2013145","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"5292_CR28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"3","key":"5292_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81(3):335\u2013343","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5292_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-025-01119-9","volume":"32","author":"C Tito","year":"2025","unstructured":"Tito C, Masciarelli S, Colotti G, Fazi F (2025) Egf receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci 32(1):24","journal-title":"J Biomed Sci"},{"key":"5292_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1453429","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Li L, Tian J, Ma L, Wu Y, Luo Q et al (2024) Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis. Front Pharmacol 15:1453429","journal-title":"Front Pharmacol"},{"issue":"5","key":"5292_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","volume":"73","author":"M Yates","year":"2021","unstructured":"Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V et al (2021) Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol 73(5):779\u2013788","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5292_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"9","key":"5292_CR34","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW et al (2016) Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 68(9):2328\u20132337","journal-title":"Arthritis Rheumatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05292-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:25Z","timestamp":1783907065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5292"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05292-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9085036\/v1","asserted-by":"object"}]},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on publicly available, anonymized data from FAERS. Because all patient information in FAERS is de-identified prior to release, no institutional review board (IRB) approval or informed consent was required. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the core practices of the Committee on Publication Ethics (COPE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}